Renalytix amends bond agreement with CVI, adds beneficial ownership cap and payment deferral rights

Renalytix plc

Amendment with CVI Investments adds a 9.99% beneficial ownership limitation on bondholder's ordinary shares.
Removes daily cap on ADS sales; shortens market price observation periods to 5 and 3 days.
Majority bondholders (>50% principal) can defer the April 7, 2024 scheduled amortization payment.
Majority bondholders also gain right to accelerate deferred April 2024 payment and future scheduled payments.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Renalytix plc amended Bond Agreement Amendment with CVI Investments, Inc. (effective 2024-03-28).

Action: amendment
Counterparty: CVI Investments, Inc.
Effective: 2024-03-28

Exact text from the filing

On March 28, 2024, Renalytix plc (the “ Company ”) entered into a second amendment and restatement agreement (“ Bond Agreement Amendment ”) with CVI Investments, Inc. (" CVI "), which amended the terms of the Company’s existing bond agreement

View on SEC.gov

284 material agreements filed in the last 30 days. Browse all material agreements →

Renalytix plc filing history →

Source: SEC EDGAR

accession 0000950170-24-038614

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.